Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

, Weston Park Hospital, Shefield.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  QB3@953—a San ... University of California (UC) research institute and biotech ... GSK to identify and facilitate collaborations to translate ... patients. The agreement formalizes a relationship ... (DPAc) team and creates a new channel for ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... Chief Executive Officer, will present a corporate overview and business ... New York City . , 22 ... 11:30 am ET at the Millennium Broadway Hotel. , ... pm ET at the St. Regis Hotel. To ...
(Date:8/26/2015)... , Aug. 26, 2015 The North ... witness a CAGR of 7.8% during the forecast period, ... ophthalmology cataract surgery devices market in 2014 and accounted ... ophthalmology cataract surgery devices market is expected to witness ... the increasing strategic expansion of the companies and continuous ...
Breaking Medicine Technology:QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2SciClone To Present At Two Investor Conferences On September 10, 2015 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 3
... 14 Solta Medical, Inc. (Nasdaq: SLTM ), the pioneer ... announced it has received FDA 510(k) clearance for the new ... Fraxel re:store Dual system takes the industry leading ... 1927 nm wavelength, the first ever application of a Thulium laser ...
... 14 Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... tender offer for a portion of its outstanding 2.875% Senior ... "Modified Dutch Auction" procedure, Par is offering to purchase, for ... up to approximately 82.7%, of the outstanding convertible notes, at ...
Cached Medicine Technology:Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 2Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 2Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 4
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider ... content is ICD-10 ready and available to all clients. All Krames Patient Education ... which are more targeted and return a more comprehensive data set of content ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... its partnership with Julia Glushko, professional Tennis player for Israel in the Women’s ... Zensah® Compression for all her training and recovery. , With a focus on ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... -- A new research study conducted by an international team ... including evidence-based guidelines for lower-risk use - to reduce the ... Led by CAMH scientist and CIHR/PHAC* Chair in Applied ... study is being published in the September/October 2011 issue of ...
... of medicines commonly given for pain -- were associated with ... adults, aged 65 to 94, e-published in advance of publication ... The study from researchers at Group Health Research Institute and ... are drugs generally given for insomnia and anxiety, did not ...
... , THURSDAY, Sept. 22 (HealthDay News) -- There ... and other recreational water in the United States in ... to two federal reports released Thursday. The 134 ... and December 2008 occurred in 38 states and Puerto ...
... HealthDay Reporter , THURSDAY, Sept. 22 (HealthDay News) -- ... prostate biopsy are hospitalized within 30 days of the procedure, ... of similarly aged men who do not get prostate biopsies can ... issue of the Journal of Urology . "The overall ...
... By Steven Reinberg HealthDay Reporter , ... containing chloroflouorocarbons (CFCs), which can damage the ozone layer, ... the U.S. Food and Drug Administration announced Thursday. ... Armstrong Pharmaceutical Inc., because it is the only inhaler ...
... of Kentucky,s Dr. Susanne Arnold and colleagues were awarded a ... reasons for the high lung cancer rates in Eastern Kentucky. ... the study began on Sept. 15. Kentucky has the ... the southeastern portion of the state those in the ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... The Blue Line UNO Splint fits small, medium, ... cushioned two-part design includes both dorsal and volar ... extension. Recommended for those experiencing symptoms of Carpal ... for busy clinics - stock one splint to ...
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
Medicine Products: